<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">PP</journal-id><journal-title-group><journal-title>Pharmacology &amp; Pharmacy</journal-title></journal-title-group><issn pub-type="epub">2157-9423</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/pp.2014.513129</article-id><article-id pub-id-type="publisher-id">PP-52706</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject><subject> Chemistry&amp;Materials Science</subject></subj-group></article-categories><title-group><article-title>
 
 
  Possible Correlation between INR and Serum Calcium
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>uukka</surname><given-names>A. Helin</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Niko</surname><given-names>Wickholm</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Hannu</surname><given-names>Kautiainen</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Heikki</surname><given-names>Vapaatalo</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Clinical Chemistry and Hematology, HUSLAB Laboratory Services, Helsinki University Hospital, Helsinki, Finland</addr-line></aff><aff id="aff2"><addr-line>Institute of Biomedicine, Pharmacology, University of Helsinki, Helsinki, Finland</addr-line></aff><aff id="aff3"><addr-line>Medcare Ltd., &amp;amp;Auml&amp;amp;aumlnekoski, Finland</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>heikki.vapaatalo@helsinki.fi(HV)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>24</day><month>12</month><year>2014</year></pub-date><volume>05</volume><issue>13</issue><fpage>1180</fpage><lpage>1184</lpage><history><date date-type="received"><day>21</day>	<month>October</month>	<year>2014</year></date><date date-type="rev-recd"><day>27</day>	<month>November</month>	<year>2014</year>	</date><date date-type="accepted"><day>20</day>	<month>December</month>	<year>2014</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Experimental and clinical studies have shown that long term anticoagulation therapy with warfarin can induce vascular calcification which is preventable by vitamin K. Osteoporosis has been shown to be associated with vascular calcification. In the present study, we wanted to see, whether INR (International Normalized Ratio), a measure of prothrombin time, and serum calcium (corrected by albumin) correlate in laboratory data of 94 anticoagulation patients on warfarin therapy. When adjusted on age and sex, there was an inverse correlation between the two variables. Clinical relevance of this observation and explanation of lowered calcium levels in blood parallel to increase in INR-values remain to be studied further.
 
</p></abstract><kwd-group><kwd>Warfarin</kwd><kwd> INR</kwd><kwd> Serum Calcium</kwd><kwd> Vascular Calcification</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>An inverse correlation between the intake of vitamin K-2 (menaquinone) and vascular calcification has been reported in humans [<xref ref-type="bibr" rid="scirp.52706-ref1">1</xref>] -[<xref ref-type="bibr" rid="scirp.52706-ref3">3</xref>] . Warfarin, an antagonist of the vitamin K has been shown to induce arterial and cardiac valvular calcification presumably by inhibiting carboxylation and thus activation of two vitamin K-dependent proteins, Matrix Gla (MGP) and Growth Arrest Specific Gene 6 (Gas-6) proteins [<xref ref-type="bibr" rid="scirp.52706-ref4">4</xref>] - [<xref ref-type="bibr" rid="scirp.52706-ref6">6</xref>] . In murine models, warfarin treatment for a few weeks induces calcification of the artery wall and heart valves [<xref ref-type="bibr" rid="scirp.52706-ref7">7</xref>] - [<xref ref-type="bibr" rid="scirp.52706-ref9">9</xref>] . This process can be prevented or retarded in animals by high intake of vitamin K [<xref ref-type="bibr" rid="scirp.52706-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.52706-ref11">11</xref>] or transglutaminase inhibitors such as quercetin or KCC-009 [<xref ref-type="bibr" rid="scirp.52706-ref12">12</xref>] . Arterial calcification has been shown to coexist with osteoporosis [<xref ref-type="bibr" rid="scirp.52706-ref13">13</xref>] . Therefore we became interested in, whether during long lasting warfarin therapy INR values would be associated with serum calcium levels of which only one study on rhesus monkeys [<xref ref-type="bibr" rid="scirp.52706-ref14">14</xref>] and one in rats [<xref ref-type="bibr" rid="scirp.52706-ref15">15</xref>] have been published.</p></sec><sec id="s2"><title>2. Materials and Methods</title><p>The material consisted of laboratory data from the Helsinki and Uusimaa District Hospital Clinical Chemistry data bank of patients of which both the INR measurement and serum calcium concentrations corrected by albumin had been requested by primary health care providers in the district area and sent to analysis in the same clinical laboratory Helsinki University Hospital Laboratory (HUSLAB) in the year 2012. Total plasma calcium levels were measured and subsequently corrected for albumin levels using a modified Payne’s formula [<xref ref-type="bibr" rid="scirp.52706-ref16">16</xref>] . Only the gender and the age of the patients, but no other clinical data, were recorded. The therapeutic anticoagulation range for INR (International Normalized Ratio) indicating prothrombin time during warfarin therapy is 2.0 - 3.0. In patients with mechanical heart valve, the recommended range is 2.5 - 3.5. The reference range of calcium corrected with albumin is 2.15 - 2.51 mmol/L in the Helsinki University Hospital Laboratory. There were a total of 54,714 INR and 224 albumin corrected calcium measurements done during 2012 in the records. To be able to compare calcium and INR levels, we limited the analysis to samples where INR and Ca levels were analyzed within 2 days from each other. Thereafter 94 cases fulfilled this criterion.</p><p>The data are presented as means with standard deviations (SD), medians or as counts with percentages. Statistical significance for the hypotheses of linearity was evaluated by using bootstrap type analysis of covariance (ANCOVA) taking gender and age values as covariates. Ninety-five percent confidence intervals (95% CI) were obtained by bias-corrected bootstrapping. The bootstrap method is significantly helpful, when the theoretical distribution of the test statistics is unknown, or in the case of violation of the assumptions. Correlation coefficients were calculated by the Spearman method. STATA 13.1. StataCorp LP (College Station, TX, USA) statistical package was used for the analyses.</p></sec><sec id="s3"><title>3. Results</title><p>From the 94 samples, one outlier with INR of 8.0 was excluded. Thus, results were analyzed from 93 patient samples. INR averaged 2.3 (median 2.4, SD 0.76), calcium averaged 2.42 mmol/L (median 2.42, SD 0.12). There was no direct correlation between INR and calcium levels (<xref ref-type="fig" rid="fig1">Figure 1</xref>). However, when adjusted to age and gender, calcium levels showed negative correlation with increasing INR (p = 0.025, adjusted for age and gender). Calcium levels lowered by 0.05 mmol/L when INR levels under the recommended treatment range 2.0 increased towards upper level of the treatment range of over 2.7 (<xref ref-type="fig" rid="fig2">Figure 2</xref>) and showed statistically significant difference (p = 0.032) between the highest and the lowest tertile.</p></sec><sec id="s4"><title>4. Discussion</title><p>Vitamin K antagonists such as warfarin are effectively used in risk reduction of venous and arterial thrombosis. They inhibit not only post-translational activation of vitamin K dependent coagulation factors but also synthesis or activation of many extrahepatic proteins and thus cause poorly known adverse effects seen both in animal experiments and human materials [<xref ref-type="bibr" rid="scirp.52706-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.52706-ref6">6</xref>] .</p><p>The calcification process is complex, but vitamin K seems to prevent vascular calcification at least in patients with chronic kidney disease [<xref ref-type="bibr" rid="scirp.52706-ref17">17</xref>] and dietary intake of vitamin K is associated with reduced risk and incidence of coronary artery calcification and coronary heart [<xref ref-type="bibr" rid="scirp.52706-ref1">1</xref>] - [<xref ref-type="bibr" rid="scirp.52706-ref3">3</xref>] . In addition to vitamin K dependent hepatic proteins (factors II, VII, IX, X, protein C and S) there are a number of extra-hepatic vitamin K dependent proteins (e.g. matrix Gla protein, osteocalcin, nephrocalcin, plaque Gla protein and proline rich Gla proteins [<xref ref-type="bibr" rid="scirp.52706-ref18">18</xref>] which might play, among other effects, a role in calcification. MGP knockout mice develop severe calcification [<xref ref-type="bibr" rid="scirp.52706-ref19">19</xref>] . Because warfarin inhibits the activation of MGP, this might be explanation for warfarin induced vascular calcification [<xref ref-type="bibr" rid="scirp.52706-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.52706-ref20">20</xref>] [<xref ref-type="bibr" rid="scirp.52706-ref21">21</xref>] .</p><p>It is not surprising that INR, a secondary measure on warfarin effect was in a rather narrow therapeutic range and that serum calcium level in otherwise healthy subjects on normal diet did not vary too much. This might be the explanation for the absence of clear correlation, even though a tendency to negative correlation between these two variables was found.</p><p>Despite of the assumed and obvious complexity of the process we tried to use simple clinical laboratory data</p><fig id="fig1"  position="float"><label><xref ref-type="fig" rid="fig1">Figure 1</xref></label><caption><title> Distribution of individual serum albumin corrected calcium concentrations vs INR (International Standardized Ratio) values (n = 93). Correlation r = −0.12 (95% CI −0.3 to 0.09, p = 0.29)</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/6-2500586x5.png"/></fig><fig id="fig2"  position="float"><label><xref ref-type="fig" rid="fig2">Figure 2</xref></label><caption><title> Albumin corrected serum calcium concentrations vs INR (international standardized ratio) divided in tertiles (I ≤ 2.0; II 2.1 - 2.6; III ≥ 2.7). Mean with 95 percent confidence intervals. Significances: I vs III p = 0.032; for linearity p = 0.025 (adjusted for gender and age)</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/6-2500586x6.png"/></fig><p>on serum calcium and INR values of the same patients taken simultaneously (i.e. within a two-day interval) to find out possible relations between these two variables. Probably due to small physiological variations in serum calcium levels and the narrow therapeutic range of the INR values, no clear correlation could be found in the total material as such. However, when adjusted to the age and gender of the patients, a significant, inverse correlation was observed between these two variables. In some studies osteoporosis has been associated with vascular calcification [<xref ref-type="bibr" rid="scirp.52706-ref22">22</xref>] - [<xref ref-type="bibr" rid="scirp.52706-ref24">24</xref>] . On the other hand, Binkley and coworkers [<xref ref-type="bibr" rid="scirp.52706-ref14">14</xref>] could not confirm vitamin K deficiency and increase of osteoporotic markers in warfarin-treated rhesus monkeys.</p><p>It is difficult to explain, why “vitamin K deficiency” by warfarin (elevation of INR) tended to decrease serum calcium. Sokolnikov and coworkers [<xref ref-type="bibr" rid="scirp.52706-ref15">15</xref>] fed young rats with vitamin K deficient food, found prolongation of prothrombin time, and in vitro in duodenal preparations reduced calcium absorption. Our recent work [<xref ref-type="bibr" rid="scirp.52706-ref25">25</xref>] showed that prolonged warfarin treatment with high doses did not change serum calcium concentrations in the rat, but increased calcium excretion in the urine by about 50%. Unfortunately, in the present laboratory data urinary excretion of calcium was not available.</p></sec><sec id="s5"><title>5. Conclusion</title><p>Even though the present data based analysis is preliminary and has many shortcomings, it raises an important question, since vitamin K inhibitor warfarin is at present the most widely used oral anticoagulant. Yet, the possible adverse effect of vascular wall calcification is not widely known. This observation should stimulate further, more extensive epidemiologic or intervention trials.</p></sec><sec id="s6"><title>Acknowledgements</title><p>We are grateful to Professor Riitta Lassila MD, PhD for her valuable support in the beginning of the project. H.V. had a grant from Finska L&#228;res&#228;llskapet, Finland.</p></sec></body><back><ref-list><title>References</title><ref id="scirp.52706-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Geleijnse, J.M., Vermeer, C., Grobee, D.E., Schurgers, L.J., Knapen, M.H.J., van der Meer, I.M., et al. (2004) Dietary Intake of Menaquinone Is Associated with a Reduced Risk of Coronary Heart Disease: The Rotterdam Study. Journal of Nutrition, 134, 3100-3105.</mixed-citation></ref><ref id="scirp.52706-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Beulens, J.W.J., Bots, M.L., Atsma, F., Bartelink, M.-A.E.L., Procop, M., Geleijnse, J.M., et al. (2008) High Dietary Menaquinone Intake Is Associated with Reduced Coronary Calcification. Atherosclerosis, 203, 489-493.http://dx.doi.org/10.1016/j.atherosclerosis.2008.07.010</mixed-citation></ref><ref id="scirp.52706-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Gast, G.C.M., de Roos, N.M., Bots, M.L., Beulens, J.W.J., Geleijnse, J.M., Witteman, J.C., et al. (2009) High Menaquinone Intake Reduces the Incidence of Coronary Heart Disease. Nutrition, Metabolism and Cardiovascular Diseases, 19, 504-507. http://dx.doi.org/10.1016/j.numecd.2008.10.004</mixed-citation></ref><ref id="scirp.52706-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Danzinger, J. (2008) Vitamin K-Dependent Proteins, Warfarin, and Vascular Calcification. Clinical Journal of the American Society of Nephrology, 3, 1504-1510. http://dx.doi.org/10.2215/CJN.00770208</mixed-citation></ref><ref id="scirp.52706-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Chatrou, M.L.L., Winkers, K., Hackeng, T.M., Reutelingsperger, C.P. and Schurgers, L.J. (2012) Vascular Calcification: The Price to Pay for Anticoagulation Therapy with Vitamin K-Antagonists. Blood Reviews, 26, 155-166. http://dx.doi.org/10.1016/j.blre.2012.03.002</mixed-citation></ref><ref id="scirp.52706-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, Y.-T. and Tang, Z.-Y. (2014) Research Progress of Warfarin-Associated Vascular Calcification and Its Possible Therapy. Cardiovascular Pharmacology, 63, 76-82. http://dx.doi.org/10.1097/FJC.0000000000000008</mixed-citation></ref><ref id="scirp.52706-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Price, P.A., Faus, S.A. and Williamson, M.K. (1998) Warfarin Causes Rapid Calcification of the Elastic Lamellae in Rat Arteries and Heart Valves. Arteriosclerosis, Thrombosis, and Vascular Biology, 18, 1400-1407. http://dx.doi.org/10.1161/01.ATV.18.9.1400</mixed-citation></ref><ref id="scirp.52706-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Howe, A.M. and Webster, W.S. (2000) Warfarin Exposure and Calcification of the Arterial System of the Rat. International Journal of Experimental Pathology, 81, 51-56. http://dx.doi.org/10.1046/j.1365-2613.2000.00140.x</mixed-citation></ref><ref id="scirp.52706-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Spronk, H.M.H., Soute, B.A.M., Schungers, L.J., Thijssen, H.H.W., De Mey, J.G.R. and Vermeer, C. (2003) Tisssue-Specific Utilization of Menaquinone-4 Results in the Prevention of Arterial Calcification in Warfarin-Treated Rats. Journal of Vascular Research, 40, 531-537. http://dx.doi.org/10.1159/000075344</mixed-citation></ref><ref id="scirp.52706-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Dao, H.H., Essalihi, R., Graillon, J.-F., Lariviere, R., de Champlain, J. and Moreau, P. (2002) Pharmacological Prevention and Regression of Arterial Remodeling in a Rat Model of Isolated Systolic Hypertension. Journal of Hypertension, 20, 1597-1606. http://dx.doi.org/10.1097/00004872-200208000-00023</mixed-citation></ref><ref id="scirp.52706-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Schungers, L.J., Spronk, H.M.H., Soute, B.A.M., Schiffers, P.M., De Mey, J.G.R. and Vermeer, C. (2007) Regression of Warfarin-Induced Medial Elastocalcinosis by High Intake of Vitamin K in Rats. Blood, 109, 2823-2831.http://dx.doi.org/10.1182/blood-2006-07-035345</mixed-citation></ref><ref id="scirp.52706-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Beazley, K.E., Banyard, D., Lima, F., Deasey, S.C., Nurminsky, D.I., Konoplyannikov, M. and Nurminskay, M.V. (2013) Transglutaminase Inhibitors Attenuate Vascular Calcification in a Preclinical Model. Arteriosclerosis, Thrombosis, and Vascular Biology, 33, 43-51. http://dx.doi.org/10.1161/ATVBAHA.112.300260</mixed-citation></ref><ref id="scirp.52706-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Rubin, M.R. and Silverberg, S.J. (2004) Vascular Calcification and Osteoporosis—The Nature of the Nexus. The Journal of Clinical Endocrinology and Metabolism, 89, 4243-4245. http://dx.doi.org/10.1210/jc.2004-1324</mixed-citation></ref><ref id="scirp.52706-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Binkley, N., Krueger, D., Engelke, J. and Suttle, J. (2007) Vitamin K Deficiency from Long-Term Warfarin Anticoagulation Does Not Alter Skeletal Status in Male Rhesus Monkeys. Journal of Bone and Mineral Research, 22, 695-700. http://dx.doi.org/10.1359/jbmr.070208</mixed-citation></ref><ref id="scirp.52706-ref15"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sokol’nikov</surname><given-names> A.A.</given-names></name>,<name name-style="western"><surname> Kodentsova</surname><given-names> V.M.</given-names></name>,<name name-style="western"><surname> Sergeev</surname><given-names> I.N. Strunin</given-names></name>,<name name-style="western"><surname> S.E. and Sklimov</surname><given-names> O.A. </given-names></name>,<etal>et al</etal>. (<year>1989</year>)<article-title>Calcium Metabolism in the Case of Vitamin D and K Deficiencies</article-title><source> Voprosy Pitaniia</source><volume> 1</volume>,<fpage> 56</fpage>-<lpage>60</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.52706-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Payne, R.B., Little, A.J., Williams, R.B. and Milner, J.R. (1973) Interpretation of Serum Calcium in Patients with Abnormal Serum Proteins. British Medical Journal, 4, 643-646. http://dx.doi.org/10.1136/bmj.4.5893.643</mixed-citation></ref><ref id="scirp.52706-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Cheung, C.L., Sahni, S., Cheung, B.M., Sing, C.W. and Wong, I.C. (2014) Vitamin K Intake and Mortality in People with Chronic Disease from NHANES III. Clinical Nutrition, in Press. http://dx.doi.org/10.1016/j.clnu.2014.03.011</mixed-citation></ref><ref id="scirp.52706-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Ferland, G. (1998) The Vitamin K-Dependent Proteins: An Update. Nutrition Reviews, 56, 223-230.http://dx.doi.org/10.1111/j.1753-4887.1998.tb01753.x</mixed-citation></ref><ref id="scirp.52706-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Luo, G., Ducy, P., McKee, M.D., Pinero, G.J., Loyer, E., Behringer, R.R. and Karsenty, G. (1997) Spontaneous Calcification of Arteries and Cartilage in Mice Lacking Matrix GLA Protein. Nature, 386, 78-81.http://dx.doi.org/10.1038/386078a0</mixed-citation></ref><ref id="scirp.52706-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Erkkil?, A.T. and Booth, S.L. (2008) Vitamin K Intake and Atherosclerosis. Current Opinion in Lipidology, 19, 39-42. http://dx.doi.org/10.1097/MOL.0b013e3282f1c57f </mixed-citation></ref><ref id="scirp.52706-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Demer, L.L. and Tintut, Y. (2014) Inflammatory, Metabolic and Genetic Mechanisms of Vascular Calcification. Arteriosclerosis, Thrombosis, and Vascular Biology, 34, 715-723. http://dx.doi.org/10.1161/ATVBAHA.113.302070</mixed-citation></ref><ref id="scirp.52706-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Frye, M.A., Melton III, L.J., Bryant, S.C., Fitzpatrick, L.A., Wahner, H.V.V., Schwartz, R.S. and Riggs, B.L. (1992) Osteoporosis and Calcification of the Aorta. Bone and Mineral, 19, 185-194.http://dx.doi.org/10.1016/0169-6009(92)90925-4</mixed-citation></ref><ref id="scirp.52706-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Szulc, P., Kiel, D.P. and Delmas, P.D. (2008) Calcifi-cations in the Abdominal Aorta Predict Fractures in Men: MINOS Study. Journal of Bone and Mineral Research, 23, 95-102. http://dx.doi.org/10.1359/jbmr.070903</mixed-citation></ref><ref id="scirp.52706-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Naves, M., Rodriguez-Garcia, M., Diaz-López, J.B. Gómez-Alonso, C. and Cannata-Andia, J.B. (2008) Progression of Vascular Calcifications Is Associated with Greater Bone Loss and Increased Bone-Fractures. Osteoporosis International, 19, 1161-1166. http://dx.doi.org/10.1007/s00198-007-0539-1</mixed-citation></ref><ref id="scirp.52706-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Siltari, A., Wickholm, N., Kivim&amp;aumlki, A.S., Olli, K., Salli, K., Tiihonen, K., Korpela, R. and Vapaatalo, H. (2014) Effects of Vitamin K-1 and Menaquinone-7 on Vascular Function and Blood Pressure in Warfarin-Induced Calcification-Model in Rats. Pharmacology &amp; Pharmacy, 5, 1095-1105. http://dx.doi.org/10.4236/pp.2014.512119</mixed-citation></ref></ref-list></back></article>